The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men

BJU International

Volumn 110, Issue 2, 2012, Pages 162-169

  Dinsmore, Wallace W ^a   Wyllie, Michael G ^b  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b Plethora Solutions Holdings PLC   (United Kingdom)

Author keywords

Buccal delivery; Hypogonadism; Late onset hypogonadism; Testosterone deficiency; Testosterone replacement; Testosterone supplement

Indexed keywords

ANDROSTANOLONE; PLACEBO; TESTOSTERONE;

ANDROGEN DEFICIENCY; APPLICATION SITE REACTION; ARTICLE; BITTER TASTE; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; ERYTHROCYTOSIS; GINGIVA DISEASE; GINGIVA PAIN; GINGIVITIS; HUMAN; HYPOGONADISM; LEUKOPENIA; LIVER METABOLISM; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; MOUTH EDEMA; MOUTH ULCER; MUCOADHESION; ORAL BLISTER; PATIENT COMPLIANCE; PATIENT PREFERENCE; POLYCYTHEMIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL;

ADMINISTRATION, BUCCAL; ADMINISTRATION, CUTANEOUS; ANDROGENS; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; GELS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MEDICATION ADHERENCE; PATIENT PREFERENCE; PRACTICE GUIDELINES AS TOPIC; TABLETS; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84863443850     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10837.x     Document Type: Article

References (28)

1. The Urology Company Ltd. Striant SR 30mg mucoadhesive buccal tablets: summary of product characteristics. 2011. Available at: http://www.medicines. org.uk/emc/medicine/24144/SPC/. Accessed November 2011
2. No authors listed. Testosterone-buccal - Columbia: COL 1621, Striant, testosterone PHBT, testosterone progressive hydration buccal tablet. Drugs R D 2003; 4: 72-4
3. Korbonits M, Kipnes M, Grossman AB. Striant SR: a novel, effective and convenient testosterone therapy for male hypogonadism. Int J Clin Pract 2004; 58: 1073-80 (Pubitemid 39642423)
4. Morales A, Schulman CC, Tostain J, Wu FC. Testosterone Deficiency Syndrome (TDS) needs to be named appropriately-the importance of accurate terminology. Eur Urol 2006; 50: 407-9 (Pubitemid 44192565)
5. Jockenhövel F, Schubert MD. Male Hypogonadism, 2nd edn. Bremen: UNI-MED Verlag AG, 2007
6. Araujo AB, Esche GR, Kupelian V et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007; 92: 4241-7 (Pubitemid 350074738)
7. Bhasin S, Cunningham GR, Hayes FJ et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 2536-59
8. Wang C, Nieschlag E, Swerdloff R et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. E ur Urol 2009; 5 5: 121-30
9. Araujo AB, O'Donnell AB, Brambilla DJ et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004; 89: 5920-6 (Pubitemid 39628393)
10. British Society for Sexual Medicine. Guidelines on the management of sexual problems in men: the role of androgens. 2010. Available at: http://www.bssm.org.uk/downloads/UK-Guidelines-Androgens-Male-2010.pdf. Acessed November 2011
11. Maggi M, Schulman C, Quinton R, Langham S, Uhl-Hochgraeber K. The burden of testosterone deficiency syndrome in adult men: economic and quality-of-life impact. J Sex Med 2007; 4: 1056-69 (Pubitemid 47079639)
12. Bassil N, Alkaade S, Morley JE. The benefi ts and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag 2009; 5: 427-48
13. Seftel A. Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profi les, monitoring, safety issues, and potential future agents. Int J Impot Res 2007; 19: 2-24 (Pubitemid 46067343)
14. Wang C, Swerdloff R, Kipnes M et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab 2004; 8 9: 3821-9 (Pubitemid 39071479)
15. Ross RJ, Jabbar A, Jones TH et al. Pharmacokinetics and tolerability of a bioadhesive buccal testosterone tablet in hypogonadal men. Eur J Endocrinol 2004; 150: 57-63 (Pubitemid 38159741)
16. Korbonits M, Slawik M, Cullen D et al. A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. J Clin Endocrinol Metab 2004; 89: 2039-43 (Pubitemid 38619830)
17. Dobs AS, Matsumoto AM, Wang C, Kipnes MS. Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. Curr Med Res Opin 2004; 20: 729-38 (Pubitemid 38685019)
18. Behre HM, von Eckardstein S, Kliesch S, Nieschlag E. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years. Clin Endocrinol (Oxf) 1999; 50: 629-35 (Pubitemid 29236340)
19. Bals-Pratsch M, Langer K, Place VA, Nieschlag E. Substitution therapy of hypogonadal men with transdermal testosterone over one year. Acta Endocrinol (Copenh) 1988; 118: 7-13
20. Swerdloff RS, Wang C, Cunningham G et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 4500-10 (Pubitemid 32157624)
21. Isidori AM, Giannetta E, Gianfrilli D et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf) 2005; 63: 381-94 (Pubitemid 41442332)
22. Isidori AM, Giannetta E, Greco EA et al. Effects of testosterone on body composition, bone metabolism and serum lipid profi le in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005; 63: 280-93 (Pubitemid 41233445)
23. Bolona ER, Uraga MV, Haddad RM et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007; 82: 20-8 (Pubitemid 46036318)
24. Dobs AS, Hoover DR, Chen MC, Allen R. Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study. J Clin Endocrinol Metab 1998; 83: 33-9 (Pubitemid 28498307)
25. Columbia Laboratories Inc. Data on fi le: a combined report of two open-label phase III, multicenter studies of COL 1621, The long-term safety, tolerability and efficacy in testosterone-deficient patients. 2004
26. Columbia Laboratories Inc. Striant: prescribing information (FDA). 2003. Available at: http://www.columbialabs.com/Collateral/Documents/English-US/ Striant%20USA-930987-0.pdf. Accessed November 2011
27. de Ronde W. Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies. Hum Reprod 2009; 24: 425-8
28. Cavender RK, Fairall M. Precocious puberty secondary to topical testosterone transfer: a case report. J Sex Med 2011; 8: 622-6